Abbott has received 510(k) clearance from the FDA for its automated, mid-volume hematology instrument, CELL-DYN Ruby™. With its advanced laser optics, this instrument offers enhanced cellular analysis and greater efficiency for laboratories performing complete blood counts (CBCs), a test routinely ordered by doctors to assess a patient’s overall health and to screen for a variety of disorders, such as anemia and infection.
A key facet of CELL-DYN Ruby is its use of laser light to differentiate cellular components. Known as Multi-Angle Polarized Scatter Separation (MAPSS™), this all-optical technology provides detailed results in easy-to-view diagrams, visually depicting changes in white blood cells, red blood cells, and platelets. CELL-DYN Ruby also underwent a multi-center medical evaluation showing clinically equivalent results with CELL-DYN Sapphire™, a higher-volume, automated analyzer introduced last year.
To streamline inventory and simplify laboratory operations, CELL-DYN Ruby requires only four reagents. Additionally, the instrument utilizes advanced yet intuitive software with online tutorials to help facilitate training.
“First pass efficiency has been a hallmark of the CELL-DYN family of analyzers and an important part of improving patient care by providing hematology results quickly,” said Harold Flynn, divisional vice president and general manager, hematology at Abbott. “CELL-DYN Ruby further enhances our instrument portfolio by bringing a premium, mid-volume analyzer to support the needs of small- to-medium-sized hospital laboratories and clinics.”